Overview
- The company expects to roll out in Mexico a long-acting HIV injectable for treatment and prevention around mid‑2026, administered every two months.
- GSK currently invests about 120 million pesos per year in clinical research in Mexico and signals plans to increase that five to ten times over the next five years if regulatory gains continue.
- Recent digitalization at Cofepris has shortened clinical-trial approvals from roughly six months to about three, with industry still pressing for faster ethics reviews.
- GSK reports roughly 90 active clinical studies in the country, mostly in phases 2 and 3 across oncology, HIV, severe respiratory diseases and autoimmune conditions, and it will run its first phase 1 trial in a Mexican public institution.
- Its RSV vaccine has Cofepris approval for adults 60 and older, with vaccinations expected to begin next year.